• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Prophylactic tranexamic acid for decreased hysterectomy blood loss

byMaren ShapiroandLeah Hawkins Bressler, MD, MPH
February 7, 2016
in Obstetrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Women who received tranexamic acid before benign hysterectomy experienced less blood loss compared to placebo.

2. No serious adverse events, including blood clots or death, were seen in the intervention group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Hysterectomy is one of the most common surgical procedures performed in the United States, where over half a million are performed each year. Even when performed for benign indications, such as fibroids or abnormal uterine bleeding, hysterectomy comes with risks. The most common complications of hysterectomy are related to intraoperative and perioperative blood loss. Tranexamic acid is an anti-fibrinolytic agent that blocks fibrin degradation, thereby promoting blood clot formation. Tranexamic acid has been shown to effectively reduce bleeding complications in many surgical and medical areas, and can be used both prophylactically and therapeutically. However, few studies have specifically assessed the benefit of tranexamic acid during gynecologic surgery. In this double-blinded randomized placebo-controlled trial, researchers investigated the effects of prophylactic treatment with intravenous tranexamic acid on bleeding complications in women undergoing elective, benign hysterectomies.

Women who received prophylactic tranexamic acid had significantly less intraoperative blood loss during hysterectomy compared to women who received a placebo. There were no serious adverse events, including blood clots, observed in the intervention group, although the study was not powered to find a significant difference. Strengths of this study included double-blinded design and a large sample size. Although weighing all used materials before and after surgery is in theory can provide a more objective means of measuring blood loss than surgeon or anesthesiologist’s estimation, many patients were calculated as experiencing negative blood loss, suggesting there may be inaccuracies in this estimation method. However, variability in blood loss estimates would not be expected to vary by randomization arm in a double-blinded trial. Larger studies powered to detect a difference in adverse events and using drop in hemoglobin as an objective measure of intraoperative blood loss would further elucidate the value of tranexamic acid as a prophylactic treatment to reduce blood loss in benign hysterectomies.

Click to read the study in AJOG

Relevant Reading: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion [Cochrane Review]

RELATED REPORTS

Characterization of prognostic markers of residual neoplastic disease following hysterectomy

Tranexamic acid decreases postoperative bleeding in non-cardiac surgery patients

Tranexamic acid is unlikely to induce signs suggestive of cerebral ischemia in the treatment of acute intracerebral hemorrhage: TICH-2 study

In-Depth [randomized controlled trial]: Women undergoing abdominal, laparoscopic, or vaginal hysterectomies for benign indications were randomized to receive either 1 gram of intravenous tranexamic acid (n = 164) or a placebo (n = 166) at the start of surgery. The primary outcome was intraoperative blood loss, measured subjectively by surgeon estimate and objectively by weighing the difference in all surgical sponges before and after the procedure. Secondary outcomes included intraoperative blood loss ≥1000 mL, ≥500 mL and reoperation due to bleeding complications, among others.

Among women undergoing hysterectomy for benign indications, those randomized to preoperative tranexamic acid experienced less subjectively and objectively measured blood loss compared to placebo (Subjective: 98.4 vs. 134.8 mL, p = 0.006; objective: 100 vs. 166 mL, p = 0.004). Women in the tranexamic acid group were less likely to experience blood loss ≥500 mL (6 vs. 21, p = 0.003) or reoperation due to postoperative bleeding (2 vs. 9, p = 0.03). No adverse events, including thromboembolism or death, were observed in either group.

Image: CC/Wiki/Mk2010

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hysterectomyTranexamic acid
Previous Post

Unenhanced magnetic resonance imaging highly sensitive and specific for acute appendicitis

Next Post

Nanoliposome allows for targeted drug delivery to treat pancreatic cancer [PreClinical]

RelatedReports

Similar outcomes after supracervical vs. total hysterectomy
Oncology

Characterization of prognostic markers of residual neoplastic disease following hysterectomy

January 4, 2023
Preoperative tumor embolization does not reduce operative blood loss
Cardiology

Tranexamic acid decreases postoperative bleeding in non-cardiac surgery patients

June 18, 2022
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Emergency

Tranexamic acid is unlikely to induce signs suggestive of cerebral ischemia in the treatment of acute intracerebral hemorrhage: TICH-2 study

March 22, 2022
No differences in pain between suture and staple C-Section closure
Emergency

Prophylactic tranexamic acid prevents significant blood loss after cesarean delivery

May 4, 2021
Next Post
Nanoliposome allows for targeted drug delivery to treat pancreatic cancer [PreClinical]

Nanoliposome allows for targeted drug delivery to treat pancreatic cancer [PreClinical]

Non-antimuscarinics show promise for overactive bladder

Non-antimuscarinics show promise for overactive bladder

2 Minute Medicine Rewind February 8, 2016

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options